12:00 AM
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BAY94-9027: Phase II/III started

Bayer began the open-label, international Phase II/III PROTECT VIII Kids trial to evaluate prophylaxis (given at least once weekly) or on-demand treatment of 25-60 IU/kg IV BAY94-9027 for about 6 months (or longer...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >